The startup’s TempO-Seq platform enables quick and inexpensive high-throughput profiling of the protein-coding transcriptome.
British startup BioClavis offers personalized diagnostics. The startup’s TempO-Seq platform enables quick and inexpensive high-throughput profiling of the protein-coding transcriptome. By using defined input sequences, the solution increases the efficiency and needs only 10 % sequencing reads as compared to RNA-Seq. The startup also develops a solution for the rapid and accurate identification of active COVID-19 infections.